DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Tolterodine Extended Release (Tolterodine Tartrate) - Summary



Tolterodine tartrate extended-release capsules contain tolterodine tartrate. The active moiety, tolterodine, is a muscarinic receptor antagonist.

Tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [ see CLINICAL STUDIES ].

See all Tolterodine Extended Release indications & dosage >>


Published Studies Related to Tolterodine Extended Release (Tolterodine)

Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. [2010]
of patients with an overactive bladder (OAB)... CONCLUSION: In patients with OAB, fesoterodine 8 mg showed superior efficacy over

Tolterodine extended release is well tolerated in older subjects. [2009]
in older subjects with overactive bladder (OAB)... CONCLUSION: The nature and frequency of AEs associated with tolterodine ER

Effect of tolterodine on gastrointestinal transit and bowel habits in healthy subjects. [2008]
Clinical trials and observations suggest that constipation is an uncommon side effect of treating overactive bladder with the muscarinic receptor antagonist tolterodine. Because muscarinic antagonism inhibits gastrointestinal motor activity, we evaluated the effects of tolterodine on bowel habits, gastrointestinal and colonic transit in healthy subjects...

The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder. [2007]
patients with overactive bladder (OAB) and urgency urinary incontinence (UUI)... CONCLUSIONS: These results indicate that tolterodine-ER maintained clinical

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. [2006]
bladder and benign prostatic hyperplasia... CONCLUSIONS: These results suggest that treatment with tolterodine ER plus

more studies >>

Clinical Trials Related to Tolterodine Extended Release (Tolterodine)

Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan) [Completed]
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the Package Insert (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3) factors considered to affect the safety and/or efficacy of this drug.

Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS) [Completed]
This is an investigator-initiated study of safety, efficacy and tolerability of dutasteride given for 18 months, including a 1-year double-blind randomized co-administration with either tolterodine ER or placebo in men suffering from lower urinary tract symptoms (LUTS) including urgency and frequency, with or without urgency urinary incontinence (i. e., overactive bladder (OAB) symptoms).

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects [Completed]
This study will evaluate the pharmacologic effects of exposure to darifenacin and tolterodine on cardiovascular parameters in healthy subjects 50 years of age and older

Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine [Completed]
To assess the effect of multiple doses of mirabegron to postmenopausal adult female subjects on the pharmacokinetics (PK) of tolterodine and its metabolites. In addition, the safety of these products will be assessed.

A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause. [Terminated]
This study is being done to compare frequency of urination during the night when women take tolterodine tablets vs. when they take placebo tablets. We will also measure whether between these two treatment conditions there are any differences in women's sleep, mood and performance on cognitive tests.

more trials >>

Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017